Why the study?
Lung transplant recipients face high risk for respiratory viral infections linked to rejection and graft dysfunction, yet standardized surveillance, prevention, and treatment methods are lacking.
This review highlights the significant impact of respiratory viral infections on lung transplant recipients, including links to acute and chronic rejection, and discusses current and emerging strategies for management.
Answers are grounded in this paper and cite their sources.
May prompt closer monitoring for respiratory viruses in lung transplant recipients; leaves open optimal prevention strategies.
Lung transplant recipients are at greater risk of respiratory viral infections as compared to other solid organ transplant recipients due to constant exposure of the allograft to the external environment. There are no standardized methods for surveillance, prevention, or treatment of these infections despite their association with increased morbidity and mortality. Various studies have linked respiratory viral infections with acute cellular rejection and chronic allograft dysfunction, and emerging data indicates a role in antibody mediated rejection. This paper will review the prevalence and impact of community acquired respiratory viruses in lung transplant recipients, review the evidence linking these viral infections to long term graft dysfunction and rejection, describe existing strategies for surveillance and prevention, and list the currently available, and promising investigational therapies.
No takes yet. Share an insight, caveat, or question.
Krishnan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: